Arginine Butyrate

Sickle Cell Anemia

Susan P. PerrinePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 89/ 100

Competitive context

135 Active assets in the Sickle Cell Anemia cohort.

Asset / Sponsor	Phase	Rating
Glutamine Ain Shams University	Phase 4	BBB
Hydroxyurea St. Jude Children's Research Hospital	Phase 4	BB
Crizanlizumab Novartis Pharmaceuticals	Phase 4	BB
FILGRASTIM St. Jude Children's Research Hospital	Phase 4	BB
MAGNESIUM METALLICUM Medical College of Wisconsin	Phase 3	BB

View all 50 →

Same molecule, other indications

Arginine Butyrate is also rated in:

beta thalassemiaDormant

B

Indicative ·

57 / 100

lymphoproliferative syndromeDormant

CCC

Indicative ·

53 / 100

Epstein-Barr virus-associated lymphoproliferative disorderDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.